FOR US HEALTHCARE PROFESSIONALS ONLY
| INVEGA TRINZA® (n=224) | INVEGA HAFYERA® (n=478) | |
|---|---|---|
| Use of anticholinergic medication* | 13% | 15% |
| Parkinsonism† | 6% | 7% |
| Akathisia‡ | 3% | 3% |
| Dyskinesia§ | 1% | 1% |
EPS=extrapyramidal symptoms.
*Use of anti-EPS medication during the double-blind phase.
†Percentage of patients with Simpson-Angus Scale Global Score >0.3 (Global Score defined as the total sum of items score divided by the number of items).
‡Percentage of patients with Barnes Akathisia Rating Scale Global Clinical Rating Score ≥2.
§Percentage of patients with a score ≥3 on any of the first 7 items or a score ≥2 on 2 or more of any of the first 7 items of the Abnormal Involuntary Movement Scale.
Note: Percentages are calculated based on the number of patients in the double-blind safety analysis set per treatment group.
References: 1. INVEGA HAFYERA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Najarian D, Turkoz I, Knight k, et al. Long-term efficacy and safety of paliperidone 6-month formulation: an open-label 2-year extension of a 1-year double-blind study in adult participants with schizophrenia. Int J Neuropsychopharmacol. 2023;26(8):537-544.
Back to Top